Corporate Communications Europe Daiichi Sankyo Europe GmbH Nadine Paschen [email protected] Tel. +49 89 7808 590 Julia Thienel [email protected] Tel. +49 89 7808 140 ...

Daiichi Sankyo Europe, (hereafter, Daiichi Sankyo) announced today multiple data presentations at the European Atherosclerosis Society (EAS) Congress ...

--Esperion Therapeutics, Inc. and Daiichi Sankyo Europe GmbH, the European headquarter organization of the Japanese pharmaceutical company Daiichi Sankyo Co., Ltd., announced today a $125 million ...

On 1 July 2006 the next step in the global integration of SANKYO COMPANY, LIMITED and DAIICHI Pharmaceutical Co., Ltd. was achieved in Europe. SANKYO's current holding company in Europe, SANKYO ...

The FINANCIAL — Daiichi Sankyo Company, Limited on February 17 announced that its European subsidiary, Daiichi Sankyo Europe GmbH Group (headquartered in Munich, Germany; hereafter, DSE), has ...

Daiichi Sankyo, Japan's third largest pharma company, is on the prowl for new biotech acquisitions in Europe that can help advance its cancer research work. And the hungry pharma player has also ...

Daiichi Sankyo Europe GmbH (hereafter, "Daiichi Sankyo") today announced that the first patient has been enrolled into the ELIMINATE-AF study. The multinational, randomised phase 3b study will ...

– Esperion to Receive $300 Million in Upfront and Near-term Milestones –– Up to $900 Million in Total Milestones –– Substantial ...

Daiichi Sankyo Europe will be responsible for commercialization in the territories. Esperion will receive an upfront cash payment of $150 million as well as $150 million upon first commercial ...

Esperion and Daiichi Sankyo Europe entered into the commercialization and licensing agreement in January 2019 in a deal that included $300 million in upfront payments with the potential of ...

Japan’s Daiichi Sankyo is looking at a reduced review time for its acute myeloid leukaemia (AML) drug quizartinib in Europe, the top prospect in its new oncology pipeline.

Earnings Call Insights: Daiichi Sankyo (OTCPK:DSKYF) Q3 2024 Management View Revenue for Q3 FY2024 increased 16.6% year-on-year to ¥1,367.6 billion, driven by growth in oncology and international ...